Phase II Study of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Newly Diagnosed (Ph+) ALL

Sponsor:

SWOG

Sponsor Study ID:

21CTP.LEUK01

CTO #:

104224

NCT Number:

NCT06773936

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lymphoid Leukemia

Study Objectives:

To assess the rate of major molecular remission (MMR) by polymerase chain reaction (PCR) for BCR-ABL at day 85 in newly diagnosed participants with Philadelphia-chromosome positive Ph+ acute lymphoblastic leukemia (ALL) treated with asciminib, dasatinib and prednisone.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)